Monitor formulary adoption trends and prescription growth in upcoming quarters to assess commercial traction. Reduced co-pay program reliance could improve margins, making Emrosi™ more profitable over time.
Price Chart
Executive Summary
Journey Medical Corporation announced that approximately 85% of commercial lives in the U.S. now have access to its rosacea treatment Emrosi™ following a contract with the third major group purchasing organization (GPO). This expands payer coverage and supports commercial growth, with management expecting improved profitability as reliance on co-pay support decreases.
Key Facts
- Approximately 85% of U.S. commercial lives now have access to Emrosi™ after contracting with the third major GPO.
- Emrosi™ is indicated for inflammatory lesions of rosacea in adults.
- Expanded payer access is expected to drive prescription demand and reduce reliance on co-pay bridging programs.
- Company emphasizes ongoing efforts toward national and regional formulary adoption throughout 2026 and beyond.
Financial Impact
Increased revenue potential from broader market access; exact figures not disclosed
Risk Factors
- Forward-looking statements subject to regulatory, commercial, and market risks
- Substantial doubt about the company's ability to continue as a going concern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G/A | $6.31 | awaiting T+20 | — | $4.94 (−21.65%) |
Aug 15, 2026 10w ago | Institutional Cluster | $6.46 $7.36 | ▲ +13.93% | ▲ +15.91% | $4.94 (−23.47%) |
Aug 12, 2026 10w ago | 8-K | $6.65 $7.23 | ▲ +8.72% | ▲ +10.47% | $4.94 (−25.65%) |
Aug 12, 2026 10w ago | Press Release | $6.65 $7.23 | ▼ −8.72% | ▼ −10.47% | $4.94 (+25.65%) |
May 13, 2026 23w ago | 8-K | $6.35 $6.34 | ▼ −0.16% | ▲ +0.70% | $4.94 (−22.14%) |
May 6, 2026 24w ago | Press Release | $5.00 $6.06 | ▲ +21.20% | ▲ +18.06% | $4.94 (−1.12%) |
Apr 21, 2026 27w ago | Press Release | $4.92 $6.25 | ▲ +27.03% | ▲ +22.12% | $4.94 (+0.49%) |
Mar 25, 2026 30w ago | Press Release | $4.78 $5.15 | ▲ +7.74% | ▼ −2.92% | $4.94 (+3.43%) |
Mar 18, 2026 31w ago | Press Release | $7.12 $5.17 | ▼ −27.39% | ▼ −33.43% | $4.94 (−30.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers